Clinical Trials Sponsored by Institut Pasteur

Total 75287 results

Sanofi Pasteur, a Sanofi Company

Completed

A Study of the Immunogenicity and Safety of the 2006-2007 Influenza Vaccine

Influenza | Orthomyxoviridae Infections

Switzerland, United Kingdom
Sanofi Pasteur, a Sanofi Company

Completed

A Study of the Immunogenicity and Safety of the 2007-2008 Influenza Vaccine

Influenza | Orthomyxoviridae Infections

United Kingdom
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity of the Inactivated Split-Virion Influenza Vaccine in Renal Transplant Subjects

Influenza | Orthomyxoviridae Infections

France
Sanofi Pasteur, a Sanofi Company

Completed

Lot-to-Lot Consistency Study of the Investigational, Inactivated, Split-Virion Influenza Vaccine in Adults

Influenza | Orthomyxoviridae Infection | Myxovirus Infection

Spain, France, Lithuania, United Kingdom
Sanofi Pasteur, a Sanofi Company

Completed

Study of Inactivated, Split-Virion Influenza Vaccine Administered by Intradermal Route Versus Vaxigrip® in Adults

Influenza | Orthomyxoviridae Infection | Myxovirus Infection

Czech Republic, Lithuania, Belgium
Sanofi Pasteur, a Sanofi Company

Completed

A Study of Japanese Encephalitis Chimeric Virus Vaccine Compared With SA14-14-2 Vaccine in Infants and Toddlers

Japanese Encephalitis | Encephalitis

Thailand
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity Study for Use of Menactra® Versus Adacel® in Subjects 11 to 55 Years of Age in South Korea

Meningitis | Meningococcal Disease

Korea, Republic of
Sanofi Pasteur, a Sanofi Company

Completed

Study of Quadrivalent Influenza Vaccine Among Adults

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Exploratory Trial to Evaluate the Safety and Immunogenicity of Menactra® and Menomune® Vaccines in Subjects ≥ 56 Years

Meningococcal Infections | Meningococcal Meningitis

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Clostridium Difficile Toxoid Vaccine (ACAM-CDIFF™) in Subjects With Clostridium Difficile Infection

Diarrhea | Clostridium Difficile Infection

United Kingdom, United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of Fluzone® Influenza Virus Vaccine 2011-2012 Formulation (Intramuscular Route) Among Adults

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

A Safety Study of IMOVAX Polio Vaccine in Selected Cities in China

Poliomyelitis | Polio

China
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Quadrivalent Influenza Vaccine Administered Intramuscularly in Children/Adolescents and Adults

Influenza

Australia, Philippines
Sanofi Pasteur, a Sanofi Company

Recruiting

Study of an Investigational Pentavalent Meningococcal ABCYW Vaccine in Adults and Adolescents

Healthy Volunteers | Meningococcal Infection | Meningococcal Immunisation

United States, Puerto Rico
Sanofi Pasteur, a Sanofi Company

Recruiting

Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy

Healthy Volunteers | Meningococcal Immunisation

Argentina
Sanofi Pasteur, a Sanofi Company

Recruiting

Observational, Passive Surveillance Program to Collect Information on Women and Their Offspring Exposed to MenQuadfi® During Pregnancy, in United States (US)

Meningococcal Infection

United States
Diaccurate SAS
CIC 1417 Cochin-Pasteur

Recruiting

Role of PLA2G1B During HIV Infection (PREDIACC)

HIV Infections

France
Sanofi Pasteur, a Sanofi Company

Completed

Study of an Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers (VAD00001)

Respiratory Syncytial Virus Infection

Honduras, United States, Chile
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe

Meningococcal Infections

Czechia, Finland, Italy, Poland, Romania, Spain, Sweden
Sanofi Pasteur, a Sanofi Company

Active, not recruiting

Study on a Live-attenuated Respiratory Syncytial Virus Vaccine for Assessment of Safety, Transmissibility, and Genetic Stability of the Vaccine Virus Among Close Contacts in Infants and Toddlers 6 to < 24 Months of Age in Puerto Rico (USA)

Respiratory Syncytial Virus Infection

United States, Puerto Rico
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adult Participants18 Years of Age and Older

Influenza Immunization

Australia, United States, Puerto Rico
Sanofi Pasteur, a Sanofi Company

Completed

Study on Two Adjuvanted Dose Levels of Panblok H7+MF59 Compared for Immunogenicity and Safety With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older

Influenza | Healthy Volunteers

United States
Sanofi Pasteur, a Sanofi Company

Active, not recruiting

Prospective Surveillance of Respiratory Syncytial Virus Disease in Infants and Toddlers

Respiratory Syncytial Virus Infections

United States, Finland, Ghana, Honduras, India, Spain, Thailand
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adults, Adolescents, Children, and Toddlers in India and Healthy Adolescents and Children in the Republic of South Africa (MET55)

Healthy Volunteers (Meningococcal Infection)

India, South Africa
Sanofi Pasteur, a Sanofi Company

Completed

A Phase I, Randomized, Modified Single-blind, Active-controlled (Infants Only), Four-stage, Step-down, Comparative, Multi-center Study

Meningococcal Immunization
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine in Infants and Toddlers When Administered Concomitantly With Routine Pediatric Vaccines in the United Kingdom (MET52)

Healthy Volunteers (Meningococcal Infection)

United Kingdom
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of a Monovalent mRNA Vaccine Encoding Influenza Hemagglutinin in Adult Participants 18 Years of Age and Older

Influenza | Influenza Immunization

United States
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the Russian Federation and Mexico (MET33)

Healthy Volunteers (Meningococcal Infection)

Mexico, Russian Federation
Sanofi Pasteur, a Sanofi Company

Completed

Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2020-2021 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively

Healthy Volunteers | Influenza Immunization

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Japanese Adults 60 Years of Age and Older

Healthy Volunteers | Influenza Immunization

Japan
Sanofi Pasteur, a Sanofi Company

Completed

Study of Purified Vero Rabies Vaccine Compared With a Reference Rabies Vaccine as Simulated Rabies Post-Exposure Prophylaxis in Adults in Thaïland

Rabies (Healthy Volunteers)

Thailand
Sanofi Pasteur, a Sanofi Company

Active, not recruiting

Study on an Investigational Yellow Fever Vaccine Compared With YF-VAX in Adults in the USA (VYF02)

Yellow Fever (Healthy Volunteers)

United States
Sanofi Pasteur, a Sanofi Company

Completed

Safety Surveillance of VaxigripTetra® and Efluelda® Influenza Vaccines in Europe During the Influenza Season 2021/22

Influenza (Healthy Volunteers)

Germany, Finland
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of a Tetravalent Dengue Vaccine in HIV-Positive Adults

Human Immunodeficiency Virus | Dengue Fever | Dengue Hemorrhagic Fever

Brazil
Sanofi Pasteur, a Sanofi Company

Completed

Safety of a Single Dose or Two Doses of Shenzhen Quadrivalent Influenza Vaccine

Influenza | Flu

China
Sanofi Pasteur, a Sanofi Company

Completed

Study of Purified Vero Rabies Vaccine Compared With Two Reference Rabies Vaccines in a Simulated Post-Exposure Regimen in Adults

Rabies (Healthy Volunteers)

France
Sanofi Pasteur, a Sanofi Company

Completed

Surveillance Study to Assess the Safety of Flublok Quadrivalent (Influenza Vaccine) in Pregnant Women and Their Offspring (VAP00007)

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study to Assess the Safety and Immunogenicity of a Single Dose of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) in Older Adults in Turkey and Lebanon (MEQ00063)

Healthy Volunteers (Meningococcal Infection)

Lebanon, Turkey
Sanofi Pasteur, a Sanofi Company

Completed

Rates of Pertussis Disease Among Persons Receiving Pentacel® or Other Pertussis Vaccines

Pertussis

United States
Sanofi Pasteur, a Sanofi Company

Completed

Zika Case Definition and Surveillance Study

Zika Virus Disease

Colombia, Honduras, Mexico, Puerto Rico
Sanofi Pasteur, a Sanofi Company

Completed

Postmarketing Surveillance Study for Use of Menactra® in the Republic of Korea

Meningitis | Meningococcal Infections | Meningococcal Meningitis

Korea, Republic of
Sanofi Pasteur, a Sanofi Company

Completed

Imovax® Rabies and VERORAB® Immunogenicity and Safety After One Week 2-sites Intradermal or 1-site Intramuscular Pre-Exposure Prophylaxis Regimens, Followed by a Simulated Post-Exposure Prophylaxis Regimen at One Year (VAJ00001)

Healthy Volunteers (Rabies Immunization)

Philippines
Sanofi Pasteur, a Sanofi Company

Completed

Postmarketing Surveillance Study for IMOJEV® in Republic of Korea

Japanese Encephalitis

Korea, Republic of
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of Verorab® in a "One-week" Intradermal Post-exposure Prophylaxis Regimen

Rabies

Philippines
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of a Purified Vero Rabies Vaccine

Rabies Virus

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Subjects

Dengue Fever | Dengue Hemorrhagic Fever | Dengue Virus | Dengue Disease

Vietnam
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of a Meningococcal Conjugate Vaccine Given Concomitantly With Other Vaccines in Toddlers

Meningitis, Meningococcal

Korea, Republic of, Mexico, Russian Federation, Thailand
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of a Booster Dose of an Investigational Quadrivalent Meningococcal Conjugate Vaccine

Meningitis | Meningococcal Infections | Meningococcal Meningitis

United States, Puerto Rico
Sanofi Pasteur, a Sanofi Company

Completed

Immune Lot Consistency, Immunogenicity, and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine

Meningitis | Meningococcal Infections | Meningococcal Meningitis

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Peruvian Children Aged 2 to 11 Years

Dengue Fever | Dengue Hemorrhagic Fever | Dengue Virus | Dengue Diseases

Peru

3

Subscribe